62 results about "Gentamycins" patented technology

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide with a broad-spectrum antibacterial effect, an antibacterial product and application. The antibacterial peptide is named as CAMP1111NC, and is obtained by performing N-terminal acetyl end capping and C-terminal amino end capping on polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide with a broad-spectrum antibacterial effect, an antibacterial product and application. The antibacterial peptide is named as CAMP502NC, and is obtained through N-terminal acetyl end capping and C-terminal amino end capping of polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention relates to application of golden larch bark acetic acid in preparation of methicillin-resistant staphylococcus aureus (MRSA) biological membrane and bacterium holding inhibitor. A biological membrane formation inhibition experiment shows that the pseudolaric acid can remarkably inhibit formation of an MRSA biological membrane, a fluorescent quantitative PCR experiment shows that the pseudolaric acid remarkably reduces transcription of related genes of the MRSA biological membrane, and a persistent bacterium killing experiment shows that the pseudolaric acid enhances the killing capability of gentamicin on MRSA persistent bacteria. Lung epithelial cell adhesion tests find that the golden larch bark acetic acid significantly reduces the adhesion effect of the MRSA strain on epithelial cells. A test for constructing an MRSA infected greater wax moth model shows that the golden larch bark acetic acid has a system protection effect on the MRSA infected greater wax moth model.

The invention discloses an amplification culture solution of TILs cells and a culture method thereof. The amplification culture solution comprises a complete culture medium, and an anti-BTLA antibody with the final concentration of 0.1-10 [mu] g / mL, penicillin with the final concentration of 50-500 [mu] g / mL, streptomycin with the final concentration of 50-500 [mu] g / mL, gentamicin with the final concentration of 10-100 [mu] g / mL and amphotericin with the final concentration of 1-50 [mu] g / mL are added into the complete culture medium. The anti-BTLA antibody component in the culture solution can relieve inhibition of BTLA on T cells by blocking combination of BTLA and a ligand HVEM of BTLA, so that the anti-tumor capability of TILs is enhanced; meanwhile, after the BTLA is combined with the ligand HVEM, T cell activation and proliferation can be inhibited, and rapid proliferation of TILs is promoted; the irradiation PBMC added in the TILs cell culture process can provide an activation signal for the TILs and drive rapid proliferation of the TILs cells.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The invention discloses a 1-N-ethyl gentamicin C1a sulfate intermediate 3, 2 ', 6'-tri-N-t-butyloxycarboryl gentamicin C1a and a preparation method thereof.The preparation method comprises the steps that gentamicin C1a and zinc acetate are subjected to a coordination reaction in methyl alcohol, and a gentamicin C1a-Zn complex is generated; reacting the gentamicin C1a-Zn complex with di-tert-butyl dicarbonate ester under the catalysis of potassium carbonate; dissolving the obtained concentrated solution in an organic solvent, adding water, shaking, standing for layering, taking an organic phase, adding an inert solvent, separating out a product solid, performing suction filtration, and drying to obtain the 3, 2 ', 6'-tri-N-t-butyloxycarboryl gentamicin C1a. The 3, 2 ', 6'-tri-N-t-butyloxycarboryl gentamicin C1a is mild in preparation condition, reaction is performed at room temperature, reaction selectivity is high, purification operation is convenient, the product yield is 98% or above, and the purity is 99% or above.

The application discloses a material for preventing tissue adhesion and hemostasis and a preparation method thereof, and relates to the technical field of medical biomaterials.The carboxymethyl cellulose, chitosan and vancomycin / ceftazidime are synergistically matched, so that the three functions of hemostasis, adhesion prevention and antibiosis are integrated;meanwhile, the water absorption and gelation of the carboxymethyl cellulose and the blood coagulation activation of the chitosan can jointly strengthen the hemostasis effect; the tissue barrier function of the chitosan and the gel isolation of the carboxymethyl cellulose can jointly improve the adhesion prevention performance; the broad-spectrum antibiosis of the vancomycin and the ceftazidime can respond to the infection risk in different surgical scenes; the material preparation process is simple, the dosage form can be adjusted according to different surgical scenes, the material has good biocompatibility and can be completely degraded, the problem that the existing medical materials have single function and are difficult to meet the needs of complex surgical wounds is solved, and the material has significant clinical application value.

The invention belongs to the field of microbial engineering, and provides a gentamicin C1a high-yield biological manufacturing method based on metabolic network modeling and reverse metabolic engineering renovation, which comprises the following steps: S1, constructing a genome scale metabolic model of a target production strain, predicting and screening a first target gene in positive correlation with gentamicin biosynthesis by using the model; s2, performing whole genome sequencing on the gentamicin high-yield mutant strain, and identifying a second target gene related to the high-yield character through comparative genomics analysis; s3, combining the first target gene predicted in the step S1 and the second target gene identified in the step S2, and constructing to obtain a recombinant engineering strain; s4, carrying out fermentation culture on the recombinant engineering strain, and supplementing materials in the fermentation process; by remarkably improving the production efficiency and strain performance of gentamicin C1a, important technical support and theoretical basis are provided for green biological manufacturing of antibiotics.

A multidimensional plasma coupling system based on Ag-coated PVP and Au-coated Ag NCs is used for surface enhanced Raman spectroscopy (SERS) detection of gentamicin, relates to the field of analysis and detection, and adopts hydrothermal synthesis to prepare Ag-coated PVP core-shell nanoparticles and Au-coated Ag core-shell cubes (Au-coated Ag NCs). Ag-coated PVP is induced to agglomerate through gentamicin, then Au-coated Ag NCs is introduced to change an electromagnetic field of nanoparticle agglomeration, a Raman characteristic peak of gentamicin is changed, and gentamicin is distinguished from a homologue of gentamicin. Under optimized experimental conditions, the linear detection range of gentamicin is 10 <-5 >-10 <-9 > M, the detection limit is 6.23 * 10 <-10 > M, and the relative standard deviation of SERS intensity is less than 10%. The method is simple and convenient to operate and high in accuracy and sensitivity, does not need a complicated operation technology, and meets the requirements of large-batch and rapid analysis and detection.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

This invention provides a human embryonic stem cell expansion culture medium, comprising DMEM / F12 medium, ITS-A, HEPES, magnesium ascorbate phosphate, non-essential amino acids, bFGF, FGF2-G3, GlutaMAX, LY-333531, gentamicin sulfate, Y27632, and CHIR99021. Y-27632 inhibits pluripotent stem cell apoptosis, improves adhesion efficiency, maintains pluripotency and colony formation ability; CHIR99021 enhances the self-renewal of pluripotent stem cells and inhibits their differentiation; LY-333531 inhibits spontaneous differentiation of pluripotent stem cells; and gentamicin sulfate reduces the risk of contamination during culture. The culture medium provided by this invention is serum-free, free of allogeneic substances, has a simple composition, and offers excellent expansion speed, effectively maintaining long-term stable passage of human embryonic stem cells, providing stable technical support for scientific research.

The invention relates to an application of glycyrrhizic acid-curcumin micelles in preparation of a medicine for treating deafness caused by gentamicin, and in the application, the glycyrrhizic acid-curcumin micelles are prepared from the following raw material medicines in percentage by weight: 66-89% of ammonium glycyrrhizinate and 11-34% of curcumin. According to the application, the glycyrrhizic acid-curcumin micelle can obviously improve hearing function impairment caused by drugs and obviously increase the fluorescent staining area of hair cells, and the effect of treating deafness caused by gentamicin is obvious.

The present invention relates to a combination of (i) a flagellin polypeptide and (ii) an antibiotic, for the simultaneous or sequential use in the treatment of bacterial infections due to Pseudomonas aeruginosa antibiotic-resistant strain. The present invention also provides a flagellin polypeptide, for use in a method for enhancing sensitivity to an antibiotic of a patient suffering from bacterial infection, due to Pseudomonas aeruginosa antibiotic-resistant strain. Indeed, using an in vivo mouse model, inventors show that while standalone prophylactic flagellin attenuates infection caused by a MDR strain of PA (PAMDR), its combination with an antibiotic such as gentamicin (GNT) leads to a strong decrease in bacterial load in the lung and a significant reduction in cell infiltration and inflammatory cytokines. Moreover, mice receiving flagellin in combination with GNT showed a 100% survival rate, a result that GNT alone was unable to provide against PAMDR.

The invention discloses application of gentamicin and ceftazidime in enhancing the drug sensitivity of serratia marcescens, and belongs to the field of biological medicine. The serratia marcescens is a strain carrying drug-resistant genes such as OqxB and mdtC, the mass ratio of gentamicin to ceftazidime is (1: 10)-(1: 50), the synergistic effect of gentamicin and ceftazidime is the strongest under the ratio, the sensitivities of serratia marcescens to gentamicin and ceftazidime can be recovered by 12.5 times and 42 times respectively, MBC is synchronously and greatly reduced, and the serratia marcescens has the dual effects of drug sensitivity enhancement and infection treatment; the single dosage is reduced, so that the cost is reduced, and the potential damage of the medicine to a host is reduced while the treatment effect is ensured. The prodigiosin is effective to serratia marcescens carrying various drug-resistant genes such as OqxB, mdtC, AAC (6 ')-Ic, KdpE and CpxA, cost is saved for prevention, control and treatment of serratia marcescens in animal husbandry, and important reference is provided for safe extraction and utilization of prodigiosin and clinical treatment of human serratia marcescens infection.

The utility model relates to injection filtering technical field, concretely is a kind of gentamicin sulfate injection filtering device, including screening box and the liquid inlet cylinder of top intercommunication thereof, the baffle is arranged in screening box and is divided into left and right two groups of screening cavities, filter cloth is arranged in each group of screening cavities, the bottom intercommunication of screening box has liquid outlet pipe, and first solenoid valve is arranged on liquid outlet pipe to control the opening and closing of liquid outlet pipe.The utility model is controlled by double screening cavities and solenoid valve interconnection design, realizes the automatic switching of filtering path, ensures production continuity and liquid processing efficiency;Combined with high-pressure flushing from bottom to top and overflow discharge mechanism, can efficiently remove blocked impurities without disassembling filter cloth, reduce downtime maintenance time, prolong filter cloth life.

The multi-dimensional plasmonic coupling system based on Ag@PVP and Au@Ag NCs for surface-enhanced Raman spectroscopy (SERS) detection of gentamicin relates to the field of analytical detection, and adopts hydrothermal synthesis to prepare Ag@PVP core-shell nanoparticles and Au@Ag core-shell cubes (Au@Ag NCs). Ag@PVP is induced to agglomerate by gentamicin, and then Au@Ag NCs are introduced to change the electromagnetic field of the nanoparticle agglomeration, so as to change the Raman characteristic peaks of gentamicin and distinguish it from its homologues. Under the optimized experimental conditions, the linear detection range of gentamicin is 10 ‑5 ~10 ‑9 M, the detection limit is 6.23 × 10 ‑10 M, and the relative standard deviation of SERS intensity is less than 10%. The method has the advantages of simple operation, high accuracy and sensitivity, and does not need complex operation technology, and meets the requirements of large quantities and rapid analysis and detection.

This invention discloses a three-dimensional multilayer sheet-like nanozyme, its preparation method, and its application in the immunochromatographic detection of small molecule environmental pollutants, belonging to the field of nanozyme and immunochromatographic detection technology. The three-dimensional sheet-like nanozyme is meticulously designed by continuously constructing Au nanoparticles (NPs) and AuPt bimetallic NPs on flexible graphene oxide (GO) nanosheets. Beneficial effects: In the nanozyme, two-dimensional GO provides a large surface area and high stability, hundreds of large AuNPs provide enhanced colorimetric ability and a large spherical surface area, and tens of thousands of AuPt satellites act as spatial catalytic sites and produce excellent peroxidase-like activity. The proposed bimodal ICA can simultaneously detect three important drugs, namely gentamicin, clenbuterol, and ractopamine, in real complex samples, greatly improving the detection performance of existing colorimetric ICA techniques based on simple catalysis, thus showing great application potential in real-time monitoring of small molecule targets under different conditions.

This application relates to a gentamicin detection kit. Specifically, the 6-glucose phosphate dehydrogenase mutant described herein comprises one or a combination of the following mutations compared to wild-type 6-glucose phosphate dehydrogenase: D306C, D375C, and G426C. The gentamicin detection kit prepared using the 6-glucose phosphate dehydrogenase mutant described herein has strong specificity, high sensitivity, ease of use, short detection time, and minimal inter-batch variability, and has promising application prospects.

The present invention provides a Bacillus subtilis strain selected from the group consisting of a) the strain deposited as DSM32324,b) the strain deposited as DSM32325, and c) a mutant strain of (a) or (b) which has sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol; and has inhibitory activity against E. coli and Clostridium perfringens. The invention further relates to Bacillus compositions comprising at least one Bacillus subtilis strain of the invention, preferably the Bacillus subtilis strain DSM32324 and / or the Bacillus subtilis strain DSM32325, as Direct Fed Microbial (DFM), premix, animal feed additive or animal feed. The invention provides a method of improving one or more animal performance parameters selected from the group consisting of i) increased weight gain (WG), ii) lower feed conversion ratio (FCR), iii) lower necrotic enteritis lesion scoring, iv) lower necrotic enteritis frequency, v) lower necrotic enteritis mortality, vi) increased European Production Efficacy Factor (EPEF), and vii) lower mortality, by feeding a strain or a composition according to the invention to an animal.

The invention discloses an embryo culture solution as well as a preparation method and application thereof, and belongs to the technical field of assisted reproduction. The technical problem to be solved is to reduce the ammonium ion concentration in the use process of the cell culture fluid. According to the technical scheme, the embryo culture solution is characterized by comprising sodium chloride, potassium chloride, monopotassium phosphate, calcium chloride, magnesium sulfate, sodium bicarbonate, a sodium lactate solution, sodium pyruvate, glucose, edetate disodium, gentamicin sulfate, human serum albumin, taurine, alanyl glutamine, non-essential amino acid and essential amino acid. The total concentration of the alanyl glutamine, the non-essential amino acid and the essential amino acid is 0.3-0.7 g / L; the mass ratio of the alanyl glutamine to the non-essential amino acid to the essential amino acid is (0.05 to 0.2) to (0.03 to 0.05) to (0.2 to 0.45); the mass ratio of the human serum albumin to the alanyl glutamine is (3-5): (0.05-0.2).

This application relates to the use of conjugates in the preparation of reagent kits. Specifically, the glucose-6-phosphate dehydrogenase mutant of this application contains a mutation selected from one or a combination of the following, compared to the wild-type glucose-6-phosphate dehydrogenase: D306C, D375C, and G426C. Gentamicin detection kits prepared using the glucose-6-phosphate dehydrogenase mutant of this application exhibit high specificity, high sensitivity, ease of operation, short detection time, and small batch-to-batch variation, demonstrating promising application prospects.

The invention relates to the technical field of microorganisms, and particularly discloses a pseudomonas aeruginosa bacteriophage T35 and application thereof, the bacteriophage is preserved in China General Microbiological Culture Collection Center on January 20, 2025, and the preservation number is CGMCC NO.46372; the phage T35 disclosed by the invention can be used for effectively inhibiting the growth of pseudomonas aeruginosa when the MOI is 10, 1 and 0.1; within 18 hours after the phage is added, the formation of a pseudomonas aeruginosa biofilm is obviously inhibited; within 12 hours after the phage is added, the formed pseudomonas aeruginosa biofilm can be removed; within 12 hours, when the titer of the phage is 10 < 6 > PFU / mL, the activity of inhibiting pseudomonas aeruginosa is superior to that of ampicillin and cefoperazone; and within 8 hours, when the titer of the phage is 10 < 6 > PFU / mL, the activity of inhibiting pseudomonas aeruginosa is superior to that of gentamicin and ciprofloxacin.

The application relates to a preparation method of a gentamicin detection reagent. Specifically, a 6-phosphogluconate dehydrogenase mutant of the application comprises one mutation or a combination thereof selected from D306C, D375C and G426C compared with wild-type 6-phosphogluconate dehydrogenase. A gentamicin detection kit prepared by using the 6-phosphogluconate dehydrogenase mutant of the application has the advantages of high specificity, high sensitivity, convenient operation, short detection time, small batch difference and good application prospect.

The present invention provides an antimicrobial combination comprising three different antimicrobial agents. The first antimicrobial agent is selected from the group consisting of ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives thereof; the second antimicrobial agent is selected from the group consisting of zidovudine, doxycycline, fosfomycin and pharmaceutically acceptable derivatives thereof; and the third antimicrobial agent is selected from the group consisting of levofloxacin, doxycycline, fosfomycin, meropenem, rifampicin, gentamicin, polymyxin B / E, and pharmaceutically acceptable derivatives thereof; wherein the combination comprises at least one of levofloxacin, doxycycline, rifampicin, fosfomycin, or a pharmaceutically acceptable derivative thereof; with the proviso that the combination is not (1) polymyxin E / B, zidovudine and rifampicin or (2) ceftazidime, zidovudine and fosfomycin. Also provided are antimicrobial combinations comprising three antimicrobial agents, wherein the first antimicrobial agent is ceftazidime or a pharmaceutically acceptable derivative thereof; the second antimicrobial agent is zidovudine or a pharmaceutically acceptable derivative thereof; and the third antimicrobial agent is polymyxin E or a pharmaceutically acceptable derivative thereof.

The invention provides application of synergy of ethyl ferulate and antibiotics in preparation of a synergistic antibacterial drug for escherichia coli O157: H7, and belongs to the technical field of antibacterial drugs. The invention firstly provides an application of ethyl ferulate in preparation of a medicine for resisting a biofilm inhibitor, and provides an application of ethyl ferulate and antibiotics in preparation of a synergistic antibacterial medicine for escherichia coli O157: H7 based on the application of ethyl ferulate and antibiotics in preparation of a synergistic antibacterial medicine for escherichia coli O157: H7. The invention proves that the ethyl ferulate has a remarkable inhibition effect on the formation of an escherichia coli O157: H7 biofilm for the first time. The invention also proves that when the ethyl ferulate is combined with the existing antibiotics (fosfomycin sodium, cefquinome, gentamicin, tetracycline and azithromycin), a synergistic effect can be generated. Therefore, the ethyl ferulate is thought to have dual effects of resisting the biofilm and synergistically resisting bacteria on the escherichia coli.

The invention discloses a method for detecting influence of bacteria on tumor cell proliferation based on CCK8, which is characterized by comprising the following steps: adding a trigeminy antibiotic culture medium containing penicillin-streptomycin-gentamicin into a bacteria and cell co-culture system to treat the co-culture system; comprising the following steps: centrifuging a cell suspension, discarding a supernatant, adding an antibiotic-free DMEM culture medium, uniformly mixing, and adding cells into a 96-well plate for overnight culture; centrifuging fresh bacterial liquid, discarding supernatant, adding a DMEM (Dulbecco Modified Eagle Medium) without antibiotics, uniformly mixing, adding bacteria into a 96-well plate, culturing, discarding an original culture medium, adding a DMEM containing penicillin-streptomycin-gentamicin antibiotics, and culturing; the method comprises the following steps of: sucking and abandoning a culture medium in a 96-well plate, adding a DMEM (Dulbecco Modified Eagle Medium) containing 10vt% of CCK8 reagent, measuring an absorbance value by using a microplate reader, and judging the influence of bacteria on tumor cell proliferation. The method has the advantages of higher stability and repeatability, and more reliable experimental result.

This invention relates to the field of immunology, and more particularly to a hybridoma cell line and its secreted monoclonal antibody against the metamizole residue marker 4-methylaminoantipyrine (MAA), and its applications. This invention uses 4-aminoantipyrine to react with methyl 4-bromomethylbenzoate, followed by alkaline hydrolysis to obtain a hapten (Formula I). ​​An immunogen is then synthesized and used to immunize mice. After cell fusion and screening, a hybridoma cell line capable of secreting a monoclonal antibody recognizing MAA is prepared, named Metamizole-6A4. This hybridoma cell line has a high efficiency in secreting monoclonal antibodies. The secreted monoclonal antibody can accurately detect MAA, IC50, and other markers. 50 The concentration is 4.06 ng / mL, with high specificity. Cross-reactivity with aminopyrine and its metabolites 4-aminoantipyrine, 4-formamidoantipyrine, 4-acetamidoantipyrine, sulfadiazine, norfloxacin, lincomycin, tylosin, penicillin G, streptomycin, and gentamicin is less than 5%. It can accurately detect MAA residues in food. Formula I.

The present invention discloses a preparation method of a membrane-coated drug sustained-release stent. First, a gentamicin-sodium alginate-polyvinyl alcohol mixed solution is prepared. By using impregnation oscillation, gel modification and cross-linking, and freeze-drying techniques, a degradable drug-coated membrane for drug sustained release is constructed on the surface of a porous stent. After that, an effective drug sustained-release effect is achieved, and it has a bactericidal and antibacterial effect for a certain period of time. It has good practicability, non-toxicity, and biodegradability, and can be used for preventing infection after bone repair surgery.

The application belongs to the technical field of microorganisms, and discloses a method for inducing formation of living unculturable state bacteria in the presence of host cells and application thereof. The method is as follows: cells in the 3th to 20th generation are transferred to a well plate to obtain induced cells; bacteria in the logarithmic growth phase are washed by a buffer, and modified cell culture solution is resuspended to obtain a bacterial suspension. The bacterial suspension is added to the induced cells, and after incubation in a constant-temperature incubator for 1-5 hours, 10-500 mg / L gentamicin-containing modified cell culture solution is added. After cell treatment for 3-10 days, intracellular bacteria are collected by adding cell lysis solution, and then washed, centrifuged and resuspended to obtain living unculturable state bacteria. The application can induce bacteria to enter the living unculturable state in the presence of host cells, which not only expands the understanding of living unculturable state bacteria, but also provides theoretical and technical support for recurrent and chronic infectious diseases in clinical practice.

The present invention relates to a pharmaceutical composition for preventing or treating hearing loss or tinnitus, comprising visomitin as an active ingredient. In the present invention, visomitin significantly inhibited ROS production induced by gentamicin or cisplatin treatment. In particular, visomitin exhibited an effect of inhibiting the cytotoxicity of gentamicin in an HEI-OC1 cell line and in cochleas extracted from mice in vitro experiments. In addition, in an in vivo experiment using zebrafish, visomitin significantly inhibited ROS generation in hair cells and apoptosis of hair cells caused by gentamicin treatment. The results demonstrate a superior improvement effect compared to antioxidants used as control drugs, and it is considered that visomitin can be used for preventing or treating hearing loss caused by toxicity of antibiotics or anticancer drugs.